Keyphrases
LMB-100
66%
Recombinant Immunotoxin
38%
Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs)
33%
Immunotoxin
33%
Antibody Formation
33%
Mesothelin
33%
Electrospun Scaffolds
33%
Anti-drug Antibodies
33%
Tofacitinib
33%
Epigenetic Landscape
33%
Tumor Epigenetics
33%
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
33%
Neuroendocrine Tumor
33%
Cobimetinib
33%
Pancreatic Cancer
33%
CASPER
33%
L-asparaginase
33%
Phase I Trial
33%
Asparagine Synthetase
25%
Asparagine
25%
Solid Tumors
19%
Front Resistance
16%
Analogue Peptide
16%
Metastatic Pancreatic Ductal Adenocarcinoma
16%
Pancreatic Ductal Adenocarcinoma
16%
MEK Inhibitor (MEKi)
16%
Tumor Killing
16%
Neutralizing Anti-drug Antibodies
11%
Glioblastoma Resection
11%
Pericarditis
11%
3-cycle
11%
Tumor Pathogenesis
11%
Figitumumab
8%
Clinical Benefit
8%
Glutamine
8%
Advanced or Metastatic
8%
Tolerability
8%
Starvation
8%
Tumor Cell Resistance
8%
Treatment Strategy
8%
RAS-MAPK Signaling
8%
Auxotrophic Strains
8%
Aspartate
8%
Clinical Utility
8%
Pegylated Asparaginase
8%
Nanofiber Scaffold
6%
Elastic Cartilage
6%
Phase 1 Trial
5%
Appendiceal Carcinoma
5%
Glioblastoma Spheroid
5%
Medicine and Dentistry
Glioblastoma
66%
Stem Cell Therapy
39%
Malignant Neoplasm
38%
Stem Cell
36%
Beta-Catenin
33%
Molecular Scaffold
33%
Adenomatous Polyposis Coli
33%
Nodular Melanoma
33%
Transplantation
33%
Clinical Significance
33%
Umbilical Cord-Derived Mesenchymal Stem Cell
33%
Colorectal Liver Metastasis
33%
Floxuridine
33%
Hepatic Arterial Infusion
33%
Surgery
30%
Drug Dose Reduction
22%
Mesenchymal Stem Cell
18%
Oxodotreotide Lu 177
16%
Recurrent Disease
12%
Neoplasm
11%
Brain Metastasis
9%
Brain Cancer
9%
Overall Survival
7%
Figitumumab
6%
Elastic Cartilage
6%
Xenograft
6%
Infusion Therapy
5%
Disease Clearance
5%
Hepatectomy
5%
Histone Modification
5%
Immunology and Microbiology
Immunotoxin
100%
Mesothelin
73%
Capillary
38%
Drug Antibody
38%
Tofacitinib
33%
Arm
26%
T-Helper Cell
20%
Cytotoxic T-Cell
13%
Cytokine
12%
Pericarditis
11%
HLA-DR
6%
CD38
6%
Regulatory T Cell
6%
Optimal Drug Dose
6%
Immunocompetent Cell
6%
Immunosuppressive Drug
5%
Surface Property
5%
Glycoprotein
5%
Exotoxin
5%
Cell Surface
5%
Blood Level
5%
Tumor Volume
5%
Tumor Necrosis Factor
5%
Murine
5%
Antineoplastic Activity
5%
Transgenics
5%
Myeloid
5%
T Cell Subset
5%
Parenchyma
5%
Pseudomonas
5%
Preclinical Study
5%
